SEM images (a) 5LZCM (b) 10LZCM (c) 15LZCM. by Md. Abu Daud (21485629)

Subjects:

XRD pattern of the fabricated LZCM composites. by Md. Abu Daud (21485629)

Subjects:

Effect of ZrO₂ Addition on CTE. by Md. Abu Daud (21485629)

Subjects:

(A) Mobility distance (B) Explored areas, (C) Immobility time for open field test. by Hammad Ismail (4227988)

(A) Immobility time, (B) Frozen events for forced swim test. by Hammad Ismail (4227988)

(A) Time spent in light compartment, (B) Number of transitions between compartments, (C) Number of head pokes to light compartment for light-dark compartment test. by Hammad Ismail (4227988)

(A) Mobility rate, (B) Explored areas, (5C) Immobility time, (D) Frozen events for hole board test. by Hammad Ismail (4227988)

(A) Duration of contacts, (B) Distance covered, (C) Number of interacting contacts, (D) Number of frozen events for social interaction test. by Hammad Ismail (4227988)

(A) Number of crossings, (B) Number of rearings, (C) Latency time for novel object, (D) Familiar object exploration time, (E) Novel object exploration time for novel object recogni... by Hammad Ismail (4227988)

(A) Time taken to reach platform in hidden trail, (B) Time taken to reach platform in visible trail, (C) Latency time to reach platform zone and (D) Time spent in platform zone in... by Hammad Ismail (4227988)

(A) Time spent in closed arm, (B) Time spent in open arm, (C) Number of entries in closed arm, (D) Number of entries in open arm, and (E) Latency time to enter open arm for elevate... by Hammad Ismail (4227988)

Impact of temperature on efflux pump inhibitors in mediating ethidium bromide accumulation in <i>Mycobacterium abscessus</i>. by Timilehin Faboro (20175963)

Effect of glucose and efflux pump inhibitors on the efflux of ethidium bromide by <i>Mycobacterium abscessus</i>. by Timilehin Faboro (20175963)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

NMP inhibits the incorporation of ¹⁴C-palmitic acid into glycopeptidolipids, phosphatidylethanolamine and cardiolipin in <i>M</i>. <i>abscessus</i>. by Timilehin Faboro (20175963)

Biological and psychobehavioral variables associated with academic performance in relation to increased stress. by Juan Luis Castillo-Navarrete (20460836)

Types of Bayesian spatiotemporal models. by Weiwei Meng (304234)

Subjects:

Ecological regression model fitting results. by Weiwei Meng (304234)

Subjects: